IP Library Granted Patent US 11,607,420
Granted Patent B2
US 11,607,420 · App. 16/972,478 · Granted Mar 21, 2023

Formulation

Inventors: Elger Funda (Kaiseraugst, CH); Odile Krainz (Kaiseraugst, CH)
Assignee: DSM IP ASSETS B.V.
A61K31/655A61K9/2081A61K9/2095A61K9/5015A61K9/5026A61K9/5036A61K9/5042A61K9/5047A61K9/5063A61K9/5089A61K31/525A61K31/606
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,607,420
App. No.
16/972,478
Granted
Mar 21, 2023
Kind
B2
Abstract

The present invention relates to a new formulation of specific nutritional ingredients (nutraceuticals) and/or pharmaceutical compounds.

Claims (16)

1. A multiple unit pellet system in the form of a tablet having a weight of 100 to 1000 mg which comprises a compressed mixture of pellets (a) and particles (b), wherein

each of the pellets (a) has a coating layer of a coating material and comprises 15-75 wt. %, based on total weight of the pellets (a), of riboflavin, and wherein

each of the particles (b) comprise at least one aminosalicylate and/or at least a pharmaceutically acceptable salt and/or at least one prodrug thereof.

2. The multiple unit pellet system according to claim 1 , which further comprises at least one auxiliary ingredient.

3. The multiple unit pellet system according to claim 2 , wherein the at least one auxiliary ingredient is selected from the group consisting of binders, fillers, lubricants, proteins, dyes, flavours, sweeteners, minerals, and antioxidants.

4. The multiple unit pellet system according to claim 2 , wherein the total amount of the auxiliary ingredients is up to 99 wt. %, based on the total weight of the tablet.

5. The multiple unit pellet system according to claim 1 , wherein the particles (b) comprise at least one aminosalicylate and/or at least a pharmaceutically acceptable salt and/or at least one prodrug thereof which is selected from the group consisting of 4-aminosalicylic acid, Balsalazide, Olsalazine, Sulfasalazine and Mesalazine (5-Aminosalicylic acid).

6. The multiple unit pellet according to claim 1 , wherein the coating material is selected from the group consisting of ogcellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropyl methyl cellulose phthalate (HPMCP), methacrylic acid copolymers, shellac, fats, alginate, chitosan, pectin, cyclodextrin and gums.

7. The multiple unit pellet according to claim 6 , wherein the coating layer of the coating material on the pellets (a) has a thickness of 50-70 μm.

8. The multiple unit pellet according to claim 7 , wherein the coating material is present in an amount which is 5-60 wt. %, based on the total weight of the pellets (a).

9. A process for the production of the multiple unit pellet system according to claim 1 , comprising the steps of:

(i) providing the pellets (a) and the particles (b);

(ii) coating at least the pellets (a) with a coating material;

(iii) forming a compressible mixture by mixing the pellets (a) and the particles (b);

(iv) optionally adding other ingredients to the compressible mixture formed according to step (iii); and

(v) compressing the compressible mixture into the tablet form of the multiple unit pellet system.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2020
From: FUNDA, ELGER; KRAINZ, ODILE
To: DSM IP ASSETS B.V.
Reel/Frame 054552/0290 →
Priority Claims (2)
EP 18176695 · Jun 8, 2018 · regional
EP 18182946 · Jul 11, 2018 · regional
Continuity (1)
Related Publication 20210161920A1 · Jun 3, 2021